Company Description
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Laxminarayan Bhat |
Contact Details
Address: 10080 N. Wolfe Road, Suite SW3-200 Cupertino, California 95014 United States | |
| Phone | 408-501-8881 |
| Website | revivapharma.com |
Stock Details
| Ticker Symbol | RVPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001742927 |
| CUSIP Number | 76152G100 |
| ISIN Number | US76152G1004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laxminarayan Bhat Ph.D. | Founder, Chief Executive Officer, President and Director |
| Narayan Prabhu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | SCHEDULE 13D/A | Filing |
| Jul 1, 2025 | SCHEDULE 13D/A | Filing |
| Jul 1, 2025 | SCHEDULE 13G | Filing |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 424B5 | Filing |
| Jun 25, 2025 | 424B5 | Filing |
| Jun 6, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 30, 2025 | 424B5 | Filing |
| May 30, 2025 | 8-K | Current Report |